Abstract:
Objective This work aims to investigate the AVEN mRNA level of breast cancer and analyze its clinical significance in the treatment of breast cancer.
Methods SYBR® Green real-time quantitative polymerase chain reaction was used to determine AVEN mRNA expression in 89 breast carcinoma and para-carcinoma tissue samples.SPSS 16.0 software was employed for statistical analysis of the data.The relationship of AVEN mRNA expression with all of the clinicopathologic characteristics and risk factors was evaluated using the t test and ANOVA.The odds ratio values and their confidence intervals were calculated(95%CI).P < 0.05 was considered statistically significant.
Results The AVEN mRNA level was significantly lower in the breast cancer patients who took contraceptives than in those who did not(P=0.02).The level had no correlation with tumor size, lymph node metastasis, clinical stage, estrogen receptors, progesterone receptors, and other clinical features(P > 0.05).Furthermore, level had no relationship with the patient's age, BMI index, number of pregnancies, menopause status, menarche age, and breastfeeding, as well as risk factors such as the number of years of cumulative menstruations and the years of prenatal menstruation before primiparity(P > 0.05).
Conclusion Oral contraceptives are related to the low expression of apoptosis inhibitor gene AVEN in breast tumor tissue.